Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib for Pulmonary Complications in Spontaneous SAH
NCT06439615Phase 2Not yet recruiting
- Sponsor
- Tangdu Hospital
- Start
- Aug 2024
- Primary completion
- Dec 2026
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of baricitinib in spontaneous subarachnoid hemorrhage (SAH) (2 arms), sponsored by Tangdu Hospital. Primary endpoint: Incidence of pneumonia at 14 days. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
baricitinib
03
Conditions
spontaneous subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on NCT06439615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06439615.